Seroatlas · Protein domains

Kazal domain

IPR002350

Definition

This entry represents the Kazal domain. Canonical serine proteinase inhibitors are distributed in a wide range of organisms from all kingdoms of life and play crucial role in various physiological mechanisms PMID:6996568. They interact from the canonical proteinase-inhibitor binding loop, where P1 residue has a predominant role (the residue at the P1 position contributing the carbonyl portion to the reactive-site peptide bond). These so-called canonical inhibitors bind to their cognate enzymes in the same manner as a good substrate, but are cleaved extremely slowly. Kazal-type inhibitors represent the most studied canonical proteinase inhibitors. Kazal inhibitors are extremely variable at their reactive sites. However, some regularity prevails such as the presence of lysine at position P1 indicating strong inhibition of trypsin PMID:10708867. The Kazal inhibitor has six cysteine residues engaged in disulfide bonds arranged as shown in the following schematic representation: +------------------+ | | *******************|*** xxxxxxxxCxxxxxxCx#xxxxxCxxxxxxxxxxCxxCxxxxxxxxxxxxxxxxxC | | | | | +-------------|-----------------+ +----------------------------+ 'C': conserved cysteine involved in a disulfide bond. '#': active site residue. '*': position of the pattern. The structure of classical Kazal domains consists of a central α-helix, which is inserted between two β-strands and a third that is toward the C terminus PMID:6752426. The reactive site P1 and the conformation of the reactive site loop is structurally highly conserved, similar to the canonical conformation of small serine proteinase inhibitors.

50 human proteins with this domain

Each is a reviewed human protein in the Seroatlas serome and a potential autoantibody target; this domain groups them into one antibody-relevant category. Every entry links to its own record.

Download CSV (50 proteins: gene, accession, name)

Loading the interactive Seroatlas explorer...